In the latest bit of saber rattling over trade, the Trump administration last month reportedly floated the possibility of imposing tariffs on medical products exported from Switzerland to the U.S. because pharmaceuticals appear to be causing a trade imbalance. Although such a move is far from certain, any tariffs are likely to hurt U.S. patients in particular, according to one analyst tracking the developments.

Last year, an estimated $40 billion in medicines were sent to the U.S., while Swiss imports from the U.S. amounted to about $21 billion. From the American point of view, the imbalance is largely due to pharmaceuticals, according to a recent report in Neue Zurcher Zeitung. Last year, the paper added, these products accounted for around 53% of goods exported to the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.